Sage scraps Alzheimer's program as dalzanemdor goes 0 for 2, leaving hopes resting on Huntington's

Sage Therapeutics has seen another clinical trial go up in smoke. The biotech called time on its plans to develop dalzanemdor in Alzheimer’s disease after seeing midphase data, adding to an earlier Parkinson’s flop and leaving the team looking to an upcoming readout in Huntington’s to rescue the prospect.